ASCENT1 Study

Hemoglobin levels in people living with sickle cell disease are typically lower than the average person.

Locations

11 US sites

2 Canada sites

Age

> 18 Years

Genotypes

SCD type SS, SCD type SC, SCD type Sβ0 thalassemia, SCD type Sβ+ thalassemia

Phase

2

LEARN MORE
THRIVE-132: Therapy for Reduction in VOC Readmissions with Inclacumab

The THRIVE-132 study is determining the safety and efficacy of a single dose of inclacumab, an investigational therapy, as a possible treatment to prevent readmission to the hospital for a vaso-occlusive crises (VOCs) in individuals with sickle cell disease.

Age

> 12 Years

Genotypes

All types of SCD

Phase

3

LEARN MORE
An Electronic Patient Reported Pain Assessment in Sickle Cell

“The Electronic Patient Reported Pain Assessment in Sickle Cell” study aims to gather insights into painful crises in people living with sickle cell disease.

Locations

1 USA site

Age

> 18 Years

Genotypes

SCD type SS, SCD type Sβ0 thalassemia

Phase

N/A

LEARN MORE
Hibiscus Study: An oral investigational medication for SCD

The Hibiscus Study is enrolling adults and adolescents 12 to 65 years old with a clinical diagnosis of SCD.

Age

12 - 65 Years

Genotypes

All types of SCD

Phase

2/3

LEARN MORE
THRIVE-131: A study to potentially reduce VOCs in sickle cell

The THRIVE-131 study will evaluate the safety and efficacy of an investigational therapy called inclacumab to decrease vaso-occlusive crises in participants with sickle cell disease.

Age

> 12 Years

Genotypes

SCD type SS, SCD type SC, SCD type Sβ0 thalassemia, SCD type Sβ+ thalassemia

Phase

3

LEARN MORE